News blog

US agency reverses stance on controversial diabetes drug

If ever there were a case study in the messy uncertainties of drug development, the diabetes drug Avandia (rosiglitazone) would be a prime candidate. On 25 November, US regulators removed safety restrictions that had been pasted on the drug in 2010 following concerns about heart risks. After years of debate and deliberation, Avandia can be marketed and prescribed freely again, even though, by now, sales of the drug have plummeted as people with diabetes turn to other options. 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE